CLSI M02-A10, M07-A8, M100-S20 Package

Performance Standards for Antimicrobial Disk Susceptibility Tests;Approved Standard-Tenth Edition. CLSI document M02-A10 (ISBN 1-56238-716-2)

Susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism's identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents. A variety of laboratory methods can be used to measure the in vitro susceptibility of bacteria to antimicrobial agents.

In many clinical microbiology laboratories, an agar disk diffusion method is used routinely for testing common, rapidly growing, and certain fastidious bacterial pathogens. Clinical and Laboratory Standards Institute document M02-A10-Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Tenth Edition includes a series of procedures to standardize the way disk diffusion tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described.

The supplemental information (M100 tables) presented with this standard represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02. These tables, as in previous years, have been updated and should replace tables published in earlier years. Changes in the tables since the previous edition (M100-S18) appear in boldface type and are also summarized in the front of the document.

Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;Approved Standard-Eighth Edition. CLSI document M07-A8 (ISBN 1-56238-689-1)

Susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism's identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents.

A variety of laboratory methods can be used to measure the in vitro susceptibility of bacteria to antimicrobial agents. This document describes standard broth dilution (macrodilution and microdilution [the microdilution method described in M07 is the same methodology outlined in ISO 20776-1])1 and agar dilution techniques, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described.

The supplemental information (M100 tables) presented with this standard represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in M07. These tables, as in previous years, have been updated and should replace tables published in earlier years. Changes in the tables since the previous edition (M100-S18) appear in boldface type and are also summarized in the front of the document.

Performance Standards for Antimicrobial Susceptibiliy Testing; Nineteenth Informational Supplement. CLSI document M100-S20 (ISBN 1-56238-690-5)

The Erratum to M100-S20 of 12 April 2010 is included in this download. The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI) approved standards: M02-A10-Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Tenth Edition; and M07-A8-Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. The standards contain information about both disk (M02) and dilution (M07) test procedures for aerobic bacteria.

Clinicians depend heavily on information from the clinical microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results requires that these tests be done under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents.

The tabular information presented here represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02 and M07. Users should replace the tables published earlier with these new tables. (Changes in the tables since the most current edition appear in boldface type.)